Henry Schein and Vets First Choice announce Board of Directors for Covetrus

Wed, Jan 16, 2019 | By publisher


Business

David E. Shaw to serve as chairman of the Board; Philip Laskawy to serve as Lead Independent director

 

 

Henry Schein, Inc. and Vets First Choice on Wednesday, January 16 announced their designees who will comprise the 11-member board of directors for Covetrus, the new standalone public company that will result from the planned spin-off of the Henry Schein Animal Health business and the subsequent merger with Vets First Choice. The merger is expected to be consummated on or about February 4, 2019.

As previously announced, David E. Shaw, co-founder and chairman of Vets First Choice, will become the chairman of the Board of Covetrus. Shaw has helped build a number of successful science-based companies including Ikaria and IDEXX where he was founding chair and CEO. Philip A. Laskawy, a former partner, chairman and chief executive officer of the accounting firm EY LLP, and currently the Lead Independent director on Henry Schein’s board of directors, will serve as Lead Independent director of Covetrus. The following individuals are also expected to be appointed to the other Covetrus board of directors:

  • Benjamin Shaw, president, chief executive officer of Covetrus and co-founder and chief executive officer of Vets First Choice
  • Betsy Atkins, chief executive officer of venture capital firm Baja LLC
  • Deborah G. Ellinger, senior advisor for The Boston Consulting Group and former CEO and/or president of four private-equity backed firms, including Ideal Image
  • Sandra L. Helton, former EVP and chief Financial Officer of Telephone and Data Systems, Inc.
  • Mark J. Manoff, former partner and Americas vice chair of EY
  • Edward M. McNamara, president and co-founder of venture-building company TeamLaunch, LLC
  • Steven Paladino, EVP, chief Financial Officer and Board Member of Henry Schein
  • Ravi Sachdev, partner at Clayton Dubilier& Rice
  • Benjamin Wolin, former chief executive officer and co-founder of Everyday Health and advisor for 3L Capital LLC

“Our intention has been to create a board that reflects the expansive and transformative nature of the Covetrus opportunity, and we believe that this slate of nominees achieves that in terms of calibre, diversity, independence and other qualities,” David Shaw said. “This group has a strong mix of relevant experience, global domain knowledge and extensive capabilities across key board functions that will help Covetrus scale its technology-enabled services platform across the globe and deliver upon its mission of advancing the world of veterinary medicine.”

“It is an honour to be entrusted with the role of Lead Independent Director and to join a team of such high-quality directors,” Philip Laskawy said. “At Covetrus, we will have a firm commitment to strong corporate governance as we focus on instilling a framework of accountability that drives long-term value creation.”

– Jan. 16, 2019 @ 16:55 GMT |

Tags: